liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia.
Karolinska University Hospital.
University of Copenhagen.
University of Oslo.
Soder Hospital, Stockholm.
Show others and affiliations
2007 (English)In: Scandinavian Journal of Gastroenterology, ISSN 0036-5521, Vol. 42, no 2, 221-227 p.Article in journal (Refereed) Published
Abstract [en]

Objective. Selective leukocyte apheresis is a new type of non-pharmacological treatment for patients with active ulcerative colitis and Crohn's disease. Preliminary data have indicated that this type of therapy is safe and efficacious, and large sham-controlled studies are currently in progress. In Scandinavia, a substantial number of patients with chronic inflammatory bowel disease have already received leukocyte apheresis on a compassionate use basis and the aim of this study was to report the clinical outcome and adverse events in the first patients treated. Material and methods. Clinical details of the first consecutive 100 patients with inflammatory bowel disease treated with granulocyte, monocyte/macrophage (Adacolumn) apheresis in Scandinavia were prospectively registered. Median length of follow-up was 17 months, (range 5–30). Results. The study population comprised 52 patients with ulcerative colitis, 44 patients with Crohn's disease and 4 patients with indeterminate colitis. In 97 patients the indication for Adacolumn treatment was steroid-refractory or steroid-dependent disease. Clinical remission was attained in 48% of the patients with ulcerative colitis, and an additional 27% had a clinical response to the apheresis treatment. The corresponding figures for patients with Crohn's disease were 41% and 23%, respectively. Complete steroid withdrawal was achieved in 27 out of the 50 patients taking corticosteroids at baseline. Adverse events were reported in 15 patients and headache was most frequently reported (n=7). Conclusions. Granulocyte, monocyte/macrophage apheresis treatment seems to be a valuable adjuvant therapy in selected patients with refractory inflammatory bowel disease. The risk for toxicity or severe adverse events appears to be low.

Place, publisher, year, edition, pages
2007. Vol. 42, no 2, 221-227 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-40146DOI: 10.1080/00365520600979369Local ID: 52418OAI: diva2:260995
Available from: 2009-10-10 Created: 2009-10-10 Last updated: 2010-05-17

Open Access in DiVA

No full text

Other links

Publisher's full text
In the same journal
Scandinavian Journal of Gastroenterology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 23 hits
ReferencesLink to record
Permanent link

Direct link